Novo Nordisk Sues Eli Lilly Over Misleading GLP-1 Advertising
N.R. Finch
Novo Nordisk sued Eli Lilly on July 21 in U.S. federal court, alleging Lilly's Zepbound ads use outdated trial data to claim superiority over Wegovy — and demanding an injunction plus all profits Lilly earned from the ads, in a fight that goes to the heart of a global obesity-drug market projected to hit $120 billion a year by 2030.
What did Lilly's ads actually claim?
Lilly's TV ads directly compared the two drugs: Zepbound patients lost roughly 50 pounds on average, versus only about 33 pounds on Wegovy.
The problem: that data came from an older head-to-head trial using Wegovy's 2.4 mg dose — the legacy version.
The 7.2 mg high-dose Wegovy approved in March this year was never included. This means → Lilly benchmarked its drug against an outdated competitor, tilting the comparison in its own favor.
How close are the drugs on current data?
At the 7.2 mg dose, Wegovy showed average weight loss of about 47 pounds in the latest study — "clinically comparable" to Zepbound's results in Lilly's own most rigorous trial.
In plain terms = on up-to-date numbers, the two drugs are effectively tied; Lilly's advertised 17-pound lead largely disappears.
Lilly did add a footnote about high-dose Wegovy, but Novo Nordisk called it "vague, confusing, and virtually illegible" — far from adequate disclosure.
What is Novo Nordisk asking the court to do?
The lawsuit seeks three things: a permanent injunction stopping the ads, an order for Lilly to run corrective advertising, and financial damages equal to all profits Lilly earned from the campaigns.
The ads have aired since late April and racked up more than 700 million impressions — the core evidence behind Novo's claim of "significant competitive harm."
Novo Nordisk warned it will file for a temporary restraining order within days if Lilly does not pull the ads voluntarily.
Does this lawsuit go beyond Wegovy?
The suit also targets Lilly's comparative ads for Mounjaro versus Ozempic, alleging Lilly similarly concealed higher-dose Ozempic data approved more than four years ago.
This reflects a broader pattern: Lilly's comparative campaigns systematically cherry-picked older, lower-dose competitor data.
Novo Nordisk sent a cease-and-desist letter back in April but received "no response" — Lilly refused to pull or correct the ads. This means → the lawsuit is not a surprise escalation but the result of failed private negotiations.
What does this mean for the GLP-1 market?
The global obesity-drug market is projected to reach $120 billion a year by 2030 — the prize both companies are fighting over.
Lilly currently leads on revenue; Novo Nordisk is counter-attacking with an oral weight-loss pill, strategic price cuts, and the high-dose Wegovy launch.
Whether the court grants a temporary injunction is the most important near-term development. In plain terms = if the injunction holds, Lilly's central marketing weapon gets frozen and the market narrative could shift fast.
Content is for reference only, not financial advice.